Effects of different dose of FK506 on endocrine function of pancreatic islets and damage of beta cells of pancreatic islets in a Wistar rat model

Abstract

Background and aim: To probe into the effects of different doses of FK506 on endocrine function of pancreatic islets in Wistar rats.

Methods: Wistar rats were randomly divide into control group A (0mg/kg/d) and experimental group B (1mg/kg/d), C (3mg/kg/d), D (10mg/kg/d) treated with FK506. In an intraperitoneal glucose tolerance test, plasma glucose, insulin and C-peptide were measured with a glucose analyzer and ELISA. The ultra-structure of beta cells of pancreatic islets were assayed with an electric microscope.

Results: In the intraperitoneal glucose tolerance test, the level of plasma glucose increased with an increasing of dose of FK506 and the level of plasma insulin and C-peptide decreased with an increasing of dose of FK506. The result of the plasma glucose level showed no significant difference among groups A, B, C, and D at 0 and 120 min P>or=0.05, and result of plasma glucose level show significant differences among groups A, B, C, D at 30, 60 and 90 min, P<0.05. The result of the plasma insulin level showed significant difference among groups A, B, C, and D at 0, 30, 60, 90 min P<0.05.The result of the plasma C-peptide level showed no significant difference among groups A, B, C, and D at 0 min P> 0.05, and the result of plasma C-peptide level showed significant differences in groups A, B, C, and D at 30, 60, 90 and 120 min, P<0.05.With electric microscope assay, the endocrine secretory granules decreased in experiment group. There is some vacuolization in the beta cells of pancreatic islets in group D.

Conclusion: It was shown in the study that disorders of glucose metabolism induced by FK506 were related to the dosage of FK506.

Keywords::

• FK506
• dose
• glucose
• insulin
• C-peptide

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.